ATE279446T1 - Amphiphile cyclodextrine, deren herstellung und verwendung zur auflösung von strukturierten systemen und zur einbettung von hydrophoben verbindungen - Google Patents

Amphiphile cyclodextrine, deren herstellung und verwendung zur auflösung von strukturierten systemen und zur einbettung von hydrophoben verbindungen

Info

Publication number
ATE279446T1
ATE279446T1 AT00922751T AT00922751T ATE279446T1 AT E279446 T1 ATE279446 T1 AT E279446T1 AT 00922751 T AT00922751 T AT 00922751T AT 00922751 T AT00922751 T AT 00922751T AT E279446 T1 ATE279446 T1 AT E279446T1
Authority
AT
Austria
Prior art keywords
dissolving
production
hydrophobic compounds
structured systems
amphiphilic cyclodextrins
Prior art date
Application number
AT00922751T
Other languages
English (en)
Inventor
Rachel Auzely-Velty
Bruno Perly
Florence Djedaini-Pilard
Original Assignee
Commissariat Energie Atomique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat Energie Atomique filed Critical Commissariat Energie Atomique
Application granted granted Critical
Publication of ATE279446T1 publication Critical patent/ATE279446T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Polymers & Plastics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Optics & Photonics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
AT00922751T 1999-04-29 2000-04-26 Amphiphile cyclodextrine, deren herstellung und verwendung zur auflösung von strukturierten systemen und zur einbettung von hydrophoben verbindungen ATE279446T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9905460A FR2792942B1 (fr) 1999-04-29 1999-04-29 Cyclodextrines amphiphiles, leur preparation et leur utilisation pour solubiliser des systemes organises et incorporer des molecules hydrophobes
PCT/FR2000/001102 WO2000066635A1 (fr) 1999-04-29 2000-04-26 Cyclodextrines amphiphiles, leur preparation et leur utilisation pour solubiliser des systemes organises et incorporer des molecules hydrophobes

Publications (1)

Publication Number Publication Date
ATE279446T1 true ATE279446T1 (de) 2004-10-15

Family

ID=9545038

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00922751T ATE279446T1 (de) 1999-04-29 2000-04-26 Amphiphile cyclodextrine, deren herstellung und verwendung zur auflösung von strukturierten systemen und zur einbettung von hydrophoben verbindungen

Country Status (7)

Country Link
US (1) US6858723B1 (de)
EP (1) EP1177217B1 (de)
JP (1) JP4698842B2 (de)
AT (1) ATE279446T1 (de)
DE (1) DE60014885T2 (de)
FR (1) FR2792942B1 (de)
WO (1) WO2000066635A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050255164A1 (en) * 2002-08-15 2005-11-17 Yunging Liu Solid nano pharmaceutical formulation and preparation method thereof
CN102516417B (zh) 2002-09-06 2014-12-10 天蓝制药公司 用于传递治疗剂的以环糊精为基础的聚合物
FR2850972B1 (fr) * 2003-02-07 2005-03-11 Commissariat Energie Atomique Derives de per(3,6-anhydro) cyclodextrines, leur preparation et leur utilisation pour vehiculer des elements metalliques vers des cibles biologiques ou pour decontaminer des cibles ou fluides biologiques
FR2861396B1 (fr) * 2003-10-24 2005-12-16 Commissariat Energie Atomique Derives amphiphiles de cyclodextrines,leur procede de preparation et leurs utilisations
EP1694713A1 (de) * 2003-12-18 2006-08-30 Ciba Specialty Chemicals Holding Inc. Reaktive polysaccharidderivate und herstellung und verwendung davon
US7851457B2 (en) * 2004-01-29 2010-12-14 Innovative Biologics, Inc. β-Cyclodextrin derivatives
RU2007133709A (ru) * 2005-01-28 2009-03-20 Пиннекл Фармасьютиклз, Инк. (Us) Производные в-циклодекстрина в качестве антибактериальных агентов
EA016073B1 (ru) 2006-05-19 2012-01-30 Вайэроблок С.А. Композиция для инактивации оболочечного вируса (варианты), средства на ее основе для приготовления лекарства против вирусного заболевания, для приготовления больших количеств биосовместимого дезинфицирующего средства и для приготовления покрытия, содержащий ее набор для инактивации оболочечного вируса и способ инактивации оболочечного вируса
FR2907455A1 (fr) * 2006-10-18 2008-04-25 Commissariat Energie Atomique Oligosaccharides cycliques,notamment derives de cyclodextrines amphiphiles,substitues par un ou plusieurs groupements polycycles naturels,tels que les triterpenoides.
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
FR2919872B1 (fr) * 2007-08-10 2009-12-18 Commissariat Energie Atomique Derives de cyclodextrines
JP5364923B2 (ja) * 2009-01-28 2013-12-11 学校法人福岡大学 多機能性シクロデキストリン誘導体、その包接化合物およびそれらの製造方法。
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US9051479B2 (en) * 2012-10-12 2015-06-09 Empire Technology Development Llc Paints and coatings containing cyclodextrin additives
EP2986646B1 (de) * 2013-08-09 2019-04-10 Bio-rad Laboratories, Inc. Proteindetektion mithilfe modifizierter cyclodextrinen
TW202009013A (zh) * 2018-08-14 2020-03-01 優你康光學股份有限公司 具有功能性成分的隱形眼鏡及其產品
WO2021054063A1 (ja) * 2019-09-20 2021-03-25 公立大学法人北九州市立大学 粒子および粒子の製造方法、ならびに薬剤、薬剤の製造方法、抗がん剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681868A1 (fr) * 1991-09-30 1993-04-02 Sederma Sa Nouvelles substances amphiphiles derivees de cyclodextrines et leur utilisation dans des compositions cosmetiques.
FR2736056B1 (fr) * 1995-06-29 1997-08-08 Commissariat Energie Atomique Derives de cyclodextrines, leur preparation et leur utilisation pour incorporer des molecules hydrophobes dans des systemes de tensioactifs organises

Also Published As

Publication number Publication date
DE60014885T2 (de) 2005-10-27
DE60014885D1 (de) 2004-11-18
WO2000066635A1 (fr) 2000-11-09
JP2002543249A (ja) 2002-12-17
FR2792942A1 (fr) 2000-11-03
EP1177217A1 (de) 2002-02-06
JP4698842B2 (ja) 2011-06-08
EP1177217B1 (de) 2004-10-13
US6858723B1 (en) 2005-02-22
FR2792942B1 (fr) 2001-06-08

Similar Documents

Publication Publication Date Title
ATE279446T1 (de) Amphiphile cyclodextrine, deren herstellung und verwendung zur auflösung von strukturierten systemen und zur einbettung von hydrophoben verbindungen
Qiu et al. Spiropyran-linked dipeptide forms supramolecular hydrogel with dual responses to light and to ligand–receptor interaction
Okimoto et al. The interaction of charged and uncharged drugs with neutral (HP-β-CD) and anionically charged (SBE7-β-CD) β-cyclodextrins
KR960700074A (ko) 고용해성다성분봉입체착화합물(Highy soluble multicomponent inclusion complexes containing a base type drug, an acid and a cyclodextrin)
Archontaki et al. Study on the inclusion complexes of bromazepam with β-and β-hydroxypropyl-cyclodextrins
CY1113763T1 (el) Κοκκια περιεχοντα ασταθες σε οξυ χημικο προϊον σε μεγαλη ποσοτητα
HUP9904359A2 (hu) Eljárás metilidén-malonát nanorészecskék előállítására, és adott esetben egy vagy több biológiai hatással rendelkező molekulát tartalmazó nanorészecskék
CY1106890T1 (el) Παραγωγα της ακριδινης και η χρηση τους ως φαρμακων
ATE388690T1 (de) Stabilisierung aktiver wirkstoffe durch formulierung als nanopartikuläre zusammensetzungen
ATE214290T1 (de) Cyclodextrine zur reduzierung des durch zytotoxische substanzen verursachten gefässaustritts
ATE352520T1 (de) Siliziumnanoteilchen und verfahren zur herstellung derselben
ATE243688T1 (de) Taxol derivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
BRPI0503828A (pt) formulações contendo pó, aquosas, lìquidas, não alcoólicas
CY1112274T1 (el) Νεοι ολιγοσακχαριτες, η παρασκευh τους και οι φαρμακευτικες συνθεσεις οι οποιες τους περιεχουν
CY1111095T1 (el) Υδατοδεις συνθεσεις που περιεχουν μετρονιδαζολη
Cannavà et al. Phase solubility and FTIR-ATR studies of idebenone/sulfobutyl ether β-cyclodextrin inclusion complex
PT941095E (pt) Composicoes farmaceuticas melhoradas
ATE424384T1 (de) Imidazolderivate, verfahren zu deren herstellung und deren anwendungen
NO20070669L (no) Fremgangsmate for fremstillingen av en prioksikam: betacyklodekstrininklusjonsforbindelse
EP0788373B1 (de) Neue komplexe von taxol oder taxotere und pharmazeutische zusammensetzungen
Kritskiy et al. Selective binding of methotrexate to monomeric, dimeric and polymeric cyclodextrins
Ol’khovich et al. Inclusion complexes of hydroxypropyl-β-cyclodextrin with novel cytotoxic compounds: Solubility and thermodynamic properties
ATE316086T1 (de) Clathrat von azithromycin-hydrat mit 1,2- propylenglykol, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zusammensetzung
AR076732A1 (es) Formulaciones farmaceuticas elaboradas por nanoencapsulacion y/o complejacion
Shehatta Cyclodextrins as enhancers of the aqueous solubility of the anthelmintic drug mebendazole: thermodynamic considerations

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties